Back to search
FDAFDA · Food and drugs·Recall number D-0741-2022

TETRACAINE 1% Tetracaine HCI Injection, USP, 20mg/2mL (10mg/mL), 10 x 2ml Single Use Vials per box, Rx only, Manufactured for Cameron Pharmaceuticals, LLC., NDC 42494-437-10.

Published April 13, 2022 · Recall initiated: March 14, 2022

Summary

FDA records drug Class II recall D-0741-2022, published April 13, 2022 and initiated March 14, 2022. Recalling firm: Vitae Enim Vitae Scientific, Inc.; Status: Terminated; Reported quantity: 722 boxes; Lot: Lot #: 21VTHI017, 21VTHI018, 21VTHI019, Exp 5/31/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile.

What to do

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Vitae Enim Vitae Scientific, Inc.
Distributor
Nationwide in the U.S.A
Lot
Lot #: 21VTHI017, 21VTHI018, 21VTHI019, Exp 5/31/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was TETRACAINE 1% Tetracaine HCI Injection, USP, 20mg/2mL (10mg/mL), 10 x 2ml Single Use Vials per box, Rx only, Manufactured for Cameron Pharmaceuticals, LLC., NDC 42494-437-10. recalled?

Yes. FDA published recall D-0741-2022 on April 13, 2022. Reported hazard: Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile.

What should I do if I have this product?

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit